PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT.
TL;DR
The aim of the trial is to determine whether prostate and pelvic nodal SBRT can improve outcomes for this patient group compared to prostate SBRT.
OpenAlex 토픽 ·
Prostate Cancer Diagnosis and Treatment
Advanced Radiotherapy Techniques
Prostate Cancer Treatment and Research
The aim of the trial is to determine whether prostate and pelvic nodal SBRT can improve outcomes for this patient group compared to prostate SBRT.
APA
Angela Pathmanathan, Suneil Jain, et al. (2026). PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT.. Clinical and translational radiation oncology, 58, 101126. https://doi.org/10.1016/j.ctro.2026.101126
MLA
Angela Pathmanathan, et al.. "PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT.." Clinical and translational radiation oncology, vol. 58, 2026, pp. 101126.
PMID
41732215
Abstract
PACE-NODES is a phase III randomised controlled trial for patients with high risk localised prostate cancer, planned for radical radiotherapy with at least 12 months of androgen deprivation therapy, and suitable for stereotactic body radiotherapy (SBRT). Patients are randomised to receive either prostate SBRT (control) or prostate and pelvic nodal SBRT. In both arms, treatment is given in 5 fractions delivered on alternate days over 2 weeks. The aim of the trial is to determine whether prostate and pelvic nodal SBRT can improve outcomes for this patient group compared to prostate SBRT. PACE NODES is registered on ClinicalTrials.gov (NCT05613023).